B-cell Acute Lymphoblastic Leukemia

Oncology
14
Pipeline Programs
7
Companies
12
Clinical Trials
2 recruiting
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
3
1
9
0
1
0
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Cell Therapy
350%
Monoclonal Antibody
350%
+ 8 programs with unclassified modality

Competitive Landscape

7 companies ranked by most advanced pipeline stage

Novartis
NovartisBASEL, Switzerland
7 programs
1
5
1
CTL019Phase 31 trial
CTL019Phase 21 trial
CTL019Phase 21 trial
CTL019 T-cellsPhase 21 trial
TisagenlecleucelPhase 2Cell Therapy1 trial
+2 more programs
Active Trials
NCT03595917Recruiting40Est. Nov 2027
NCT03876769Active Not Recruiting121Est. Oct 2027
NCT02435849Completed80Est. Nov 2022
+4 more trials
Amgen
AmgenTHOUSAND OAKS, CA
2 programs
2
BlinatumomabPhase 2Monoclonal Antibody1 trial
BlinatumomabPhase 2Monoclonal Antibody1 trial
Active Trials
NCT01207388Completed116Est. Jan 2019
NCT04556084Terminated2Est. Oct 2022
Acrotech Biopharma
Acrotech BiopharmaNJ - East Windsor
1 program
1
BlinatumomabPhase 2Monoclonal Antibody
Pfizer
PfizerNEW YORK, NY
1 program
1
Blinatumomab InjectionPhase 2
BioCryst Pharmaceuticals
1 program
1
forodesine hydrochloridePhase 1/21 trial
Active Trials
NCT00289562Completed20Est. Dec 2007
Leman Biotech
Leman BiotechChina - Shenzhen
1 program
1
Metabolically Armed CD19 CAR-T cellsPhase 1Cell Therapy1 trial
Active Trials
NCT05747157UnknownEst. May 2025
AbbVie
AbbVieNORTH CHICAGO, IL
1 program
1
VenetoclaxPhase 11 trial
Active Trials
NCT05016947Active Not Recruiting23Est. Dec 2026

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
NovartisCTL019
NovartisTisagenlecleucel
NovartisTisagenlecleucel
AmgenBlinatumomab
NovartisCTL019
NovartisCTL019
NovartisCTL019 T-cells
AmgenBlinatumomab
BioCryst Pharmaceuticalsforodesine hydrochloride
Leman BiotechMetabolically Armed CD19 CAR-T cells
AbbVieVenetoclax
NovartisABL001

Clinical Trials (12)

Total enrollment: 707 patients across 12 trials

NCT04094311NovartisCTL019

Study of Out of Specification for Tisagenlecleucel

Start: Nov 2019Est. completion: Apr 2027200 patients
Phase 3Recruiting
NCT05460533NovartisTisagenlecleucel

A Second Infusion (Early Reinfusion) of Tisagenlecleucel in Children and Young Adults With B-Cell Acute Lymphoblastic Leukemia(B-ALL)

Start: Jul 2022Est. completion: Jul 202730 patients
Phase 2Active Not Recruiting
NCT04156659NovartisTisagenlecleucel

Study of Tisagenlecleucel in Chinese Pediatric and Young Adult Subjects With Relapsed or Refractory B-cell ALL

Start: Nov 2021Est. completion: Nov 20270
Phase 2Withdrawn
NCT04556084AmgenBlinatumomab

Blinatumomab Bridging Therapy for BALL

Start: Jan 2021Est. completion: Oct 20222 patients
Phase 2Terminated
NCT03876769NovartisCTL019

Study of Efficacy and Safety of Tisagenlecleucel in HR B-ALL EOC MRD Positive Patients

Start: Jun 2019Est. completion: Oct 2027121 patients
Phase 2Active Not Recruiting
NCT02435849NovartisCTL019

Study of Efficacy and Safety of CTL019 in Pediatric ALL Patients

Start: Apr 2015Est. completion: Nov 202280 patients
Phase 2Completed
NCT02228096NovartisCTL019 T-cells

Study of Efficacy and Safety of CTL019 in Pediatric ALL Patients

Start: Aug 2014Est. completion: May 201975 patients
Phase 2Completed
NCT01207388AmgenBlinatumomab

Confirmatory Phase II Study of Blinatumomab (MT103) in Patients With Minimal Residual Disease of B-precursor Acute Lymphoblastic Leukemia (ALL)

Start: Nov 2010Est. completion: Jan 2019116 patients
Phase 2Completed
NCT00289562BioCryst Pharmaceuticalsforodesine hydrochloride

Forodesine Hydrochloride (BCX-1777) for B-Cell Acute Lymphoblastic Leukemia

Start: Sep 2004Est. completion: Dec 200720 patients
Phase 1/2Completed
NCT05747157Leman BiotechMetabolically Armed CD19 CAR-T cells

Safety and Efficacy of Metabolically Armed CD19 CAR-T Cells (Meta10- 19) in the Treatment of r/r B-ALL Clinical Research

Start: Feb 2023Est. completion: May 2025
Phase 1Unknown
NCT05016947AbbVieVenetoclax

Venetoclax Plus Inotuzumab for B-ALL

Start: Sep 2021Est. completion: Dec 202623 patients
Phase 1Active Not Recruiting
NCT03595917NovartisABL001

ABL001 + Dasatinib + Prednisone + Blinatumomab in BCR-ABL+ B-ALL or CML

Start: Jul 2018Est. completion: Nov 202740 patients
Phase 1Recruiting

Related Jobs in Oncology

Senior Research Associate, Immuno-Oncology

SystImmune
1h ago
$60K - $85K/yr

Research Associate I/II, Immuno-Oncology

SystImmune
1h ago

Office Administrator

SystImmune
1h ago
$60K - $80K/yr

Scientist/Sr Scientist

TwoStep Therapeutics
San Carlos
1h ago

Senior Medical Project Manager (m/f/d)

Mindpeak
Hamburg
1h ago

Working Student Active Sourcing Support (m/f/d)

Mindpeak
Hamburg
1h ago

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

1 late-stage (Phase 3) programs — potential near-term approvals
2 actively recruiting trials targeting 707 patients
7 companies competing in this space

Related Indications

Breast Cancer(530)Non-small Cell Lung Cancer(373)Prostate Cancer(371)Multiple Myeloma(244)Advanced Solid Tumors(221)Acute Myeloid Leukemia(204)Cancer(187)Neoplasms(173)Colorectal Cancer(166)Advanced Solid Tumor(165)